Trial Profile
The study of fosaprepitant in the prevention of chemotherapy induced nausea and vomiting in patients with gynecologic cancer undergoing the combination therapy of Taxens and carboplatin.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 09 Jun 2015
Price :
$35
*
At a glance
- Drugs Fosaprepitant (Primary)
- Indications Chemotherapy-induced nausea and vomiting
- Focus Therapeutic Use
- 09 Jun 2015 New trial record